Answers are grounded in this paper and cite their sources.
Aim: Inaccurate blood glucose monitoring system (BGMS) results may lead to insulin dosing errors and adverse clinical outcomes. Results & methodology: This post-hoc analysis used a model to estimate the bolus insulin dose error associated with each of the five BGMSs, for a hypothetical person with diabetes (assuming a standardized meal and target blood glucose of 100 mg/dl). Differences in dose-error distribution between BGMSs were statistically tested. The 95% dose-error range for each BGMS was (insulin units): CONTOUR®PLUS, -1.1–0.7; Accu-Chek® Active, -2.4–0.7; Accu-Chek® Performa, -2.9–0.8; FreeStyle Freedom, from -5.5 to -0.5; OneTouch® SelectSimple™, -4.1−3.0. Conclusion: The CONTOUR®PLUS BGMS was associated with a statistically significantly smaller model-estimated median bolus insulin dose-error and dosing error range, compared with the other BGMSs.
No takes yet. Share an insight, caveat, or question.
Pardo et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: